Shots:
- Pieris to receive $10M upfront and is eligible to receive $353M in development, regulatory, and commercial based milestones along with royalties on sales of PRS-342. Pieris will also contribute an undisclosed amount for manufacturing activities
- Boston to get exclusive worldwide rights to develop PRS-342 and will be primarily responsible for the development of the program, with both parties collaborating during the IND-enabling stage
- PRS-342 is a 4-1BB/GPC3 preclinical immuno-oncology Anticalin-Ab bispecific fusion protein
Click here to read full press release/ article | Ref: Business Wire | Image: Mass Device
The post Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M first appeared on PharmaShots.
